Article preview from "The Pink Sheet" June 23, 2009
Savient's Krystexxa , an orphan drug candidate for treatment-failure gout, could bring in $600 million or more in worldwide sales by 2015, considerably bumping up the firm's potential value and making it pretty enough for picking as a potential acquisition candidate - or at the very least a collaboration partner. Read on...
Article preview from "The Pink Sheet" June 23, 2009
The pegylated uricase compound showed extremely promising efficacy results in two small pivotal studies, especially in reducing tophi - an often disabling sign of chronic gout. While there were some cardiovascular signals and a high incidence of infusion reactions, on June 16 the Arthritis Drugs Advisory Committee voted 14-1 in favor of recommending approval - although risk management discussions with FDA await.
Read the rest of the article by purchasing it as a pdf online right now. Or subscribe to "The Pink Sheet" for comprehensive biopharmaceutical regulatory, legal and business analysis.
